A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Public ClinicalTrials.gov record NCT05567796. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSema, cagrilintide,semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. They will take one injection once a week. The study medicine is injected briefly with a thin needle, typically in the stomach, thighs or upper arms. Extension study: After the main study, not all participants will continue in the extension study. The study staff will tell the participant if they will continue or not into the extension study. In the extension study we will look at what happens to the participant's body weight and diseases related to excess body weight after the participant stops taking the study medicine. The main study will last for about 1½ years and the extension study will last for another 2 years.
Study identification
- NCT ID
- NCT05567796
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 3,400 participants
Conditions and interventions
Conditions
Interventions
- Cagrilintide Drug
- Semaglutide Drug
- Placebo cagrilintide Drug
- Placebo semaglutide Drug
Drug
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2022
- Primary completion
- Oct 29, 2024
- Completion
- Oct 18, 2026
- Last update posted
- Aug 30, 2026
2022 – 2026
United States locations
- U.S. sites
- 46
- U.S. states
- 21
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Univ of Alabama Birmingham | Birmingham | Alabama | 35233 | — |
| Velocity Clin Res Los Angeles | Los Angeles | California | 90017 | — |
| Velocity Clin Res Wstlke | Los Angeles | California | 90057 | — |
| Univ of Colorado at Denver | Aurora | Colorado | 80045 | — |
| OptumCare Clinical Trials LLC | Golden | Colorado | 80401 | — |
| Northeast Research Institute | Fleming Island | Florida | 32003 | — |
| South Broward Research LLC | Miramar | Florida | 33027 | — |
| Clinical Neuroscience Solution | Orlando | Florida | 32801 | — |
| Florida Inst For Clin Res | Orlando | Florida | 32825 | — |
| Florida Institute for Clinical research | Orlando | Florida | 32825 | — |
| Clinical Trial Res Assoc,Inc | Plantation | Florida | 33324 | — |
| Hope Clin Res & Wellness | Conyers | Georgia | 30094 | — |
| East West Med Res Inst | Honolulu | Hawaii | 96814 | — |
| Great Lakes Clinical Trials | Chicago | Illinois | 60640 | — |
| Endeavor Health | Skokie | Illinois | 60077 | — |
| Evanston Premier Hlthcr Res | Skokie | Illinois | 60077 | — |
| Midwest Inst For Clin Res | Indianapolis | Indiana | 46260 | — |
| Northern Pines Hlth Ctr, PC | Buckley | Michigan | 49620 | — |
| StudyMetrix Research LLC | City of Saint Peters | Missouri | 63303 | — |
| Velocity Clinical Research Binghamton | Binghamton | New York | 13905 | — |
| Comprehensive Weight Ctrl Prog | New York | New York | 10021 | — |
| University of North Carolina | Chapel Hill | North Carolina | 27514 | — |
| University of North Carolina | Chapel Hill | North Carolina | 27517 | — |
| Medication Mgmnt, LLC_Grnsboro | Greensboro | North Carolina | 27405 | — |
| PharmQuest Life Sciences LLC | Greensboro | North Carolina | 27408 | — |
| Accellacare_NC | Raleigh | North Carolina | 27609 | — |
| Accellacare | Wilmington | North Carolina | 28401 | — |
| New Venture Medical Research | Wadsworth | Ohio | 44281 | — |
| Lynn Institute of Norman | Norman | Oklahoma | 73072 | — |
| The University of Penn Center | Philadelphia | Pennsylvania | 19104-3317 | — |
| Clinical Res Collaborative | Cumberland | Rhode Island | 02864 | — |
| Medical Uni of SC Charleston | Charleston | South Carolina | 29425 | — |
| Coastal Carolina Res Ctr | North Charleston | South Carolina | 29405 | — |
| Hillcrest Clinical Research | Simpsonville | South Carolina | 29681-1538 | — |
| Spartanburg Medical Research | Spartanburg | South Carolina | 29303 | — |
| Holston Medical Group_Bristol | Bristol | Tennessee | 37620 | — |
| Holston Medical Group | Kingsport | Tennessee | 37660 | — |
| Baylr Sctt White Rs Inst, Endo | Dallas | Texas | 75226 | — |
| Velocity Clinical Res-Dallas | Dallas | Texas | 75230 | — |
| UT Southwestern Med Cntr | Dallas | Texas | 75390-9302 | — |
| DCOL Ctr for Clin Res | Longview | Texas | 75605 | — |
| Washington Cntr Weight Mgmt | Arlington | Virginia | 22206 | — |
| Health Res of Hampton Roads | Newport News | Virginia | 23606 | — |
| Selma Medical Associates | Winchester | Virginia | 22601-3834 | — |
| Capital Clin Res Ctr,LLC | Olympia | Washington | 98502 | — |
| Rainier Clin Res Ctr Inc | Renton | Washington | 98057 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 210 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05567796, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 30, 2026 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05567796 live on ClinicalTrials.gov.